Trial Summary

Taking Part

Who? Men with advanced or relapsing prostate cancer
When? The trial is open now
Where? Hospitals throughout the UK and Switzerland (STAMPEDE map)

Most men with prostate cancer are given hormone therapy, this is often effective for a short time at stopping the tumour growing. However in most cases over time the tumour will start to grow again.

The aim of this trial is to try to prevent the tumour re-growth by adding other treatment to the hormone therapy. The trial is currently using abiraterone and enzalutamide in combination with hormone therapy or radiotherapy (newly diagnosed metastatic patients only) in combination with hormone therapy. It previously tested abiraterone alone, celecoxib, docetaxel and/or zoledronic acid.

The trial is funded by the charity Cancer Research UK and the pharmaceutical companies; Sanofi-Aventis, Pfizer, Novartis, Jansen and Astellas.